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Abstract
Background: Autologous grafting, despite some disadvantages, is still considered the gold standard for
reconstruction of maxillofacial bone defects. The aim of this study was to evaluate bone regeneration using bone
marrow-derived mesenchymal stromal cells (MSCs) in a clinical trial, a less invasive approach than autologous bone
grafting. This comprehensive clinical trial included subjects with severe mandibular ridge resorption.
Methods: The study included 11 subjects aged 52–79 years with severe mandibular ridge resorption. Bone marrow
cells were aspirated from the posterior iliac crest and plastic adherent cells were expanded in culture medium
containing human platelet lysate. The MSCs and biphasic calcium phosphate granules as scaffolds were inserted
subperiosteally onto the resorbed alveolar ridge. After 4–6 months of healing, new bone formation was assessed
clinically and radiographically, as were safety and feasibility. Bone at the implant site was biopsied for micro-
computed topography and histological analyses and dental implants were placed in the newly regenerated bone.
Functional outcomes and patient satisfaction were assessed after 12 months.
Results: The bone marrow cells, expanded in vitro and inserted into the defect together with biphasic calcium
phosphate granules, induced significant new bone formation. The regenerated bone volume was adequate for
dental implant installation. Healing was uneventful, without adverse events. The patients were satisfied with the
esthetic and functional outcomes. No side effects were observed.
Conclusions: The results of this comprehensive clinical trial in human subjects confirm that MSCs can successfully
induce significant formation of new bone, with no untoward sequelae. Hence, this novel augmentation procedure
warrants further investigation and may form the basis of a valid treatment protocol, challenging the current gold
standard.
Trial registration: EudraCT, 2012-003139-50. Registered on 21 August 2013. ClinicalTrials.gov, NCT 02751125.
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Background
Bone is among the most frequently transplanted tissues,
with about 2.2 million procedures annually worldwide
[1]. In bone reconstruction procedures, surgeons harvest
autologous bone from the patient and transplant this
bone graft to the defect. This is currently regarded as
the gold standard in bone regeneration, using the
patient’s own cells and growth factors and providing
scaffolding for bone regeneration [2]. However, the pro-
cedure has several major disadvantages: harvesting re-
quires a second surgical site and provides only limited
bone stock; the two-stage procedure increases surgery
time; and patients often suffer pain and nerve damage at
the harvest site. Moreover, autologous bone has an
unpredictable resorption rate [3–5]. These factors all
increase treatment costs and patient discomfort.
In the maxillofacial region, reconstruction may be ne-
cessary to treat congenital malformations, severe facial
trauma, or resection of tumors [6, 7]. Bone defects also
occur in the maxilla and mandible, often after tooth loss,
which results in atrophy of hard and soft alveolar tissue,
and reduction of both horizontal and vertical dimen-
sions [2]. In clinical practice, patients often present with
severe alveolar ridge resorption, leaving insufficient bone
volume for optimal installation of dental implants. Vari-
ous surgical procedures have been developed to enlarge
the alveolar crest [8].
Because of the disadvantages inherent in autologous
grafting, alternative methods for bone regeneration have
been proposed, including bone substitutes of animal, hu-
man, or synthetic origin [9–12]. There are, however,
documented cases of infection associated with bone sub-
stitute materials. Furthermore, the risks of bacterial con-
tamination and immune rejection of the graft must be
considered [9]. While these procedures can be used to
reconstruct small bone defects, they are less effective in
larger defects [3, 12, 13]. Thus, there is currently an un-
met clinical need for effective, safe interventions which
do not expose the patient to the risk of donor site mor-
bidity [14–18].
Multipotent stromal cells or mesenchymal stem cells
(MSCs) are the cells most extensively investigated and
applied [19–30]. These cells are nonhematopoietic and
of mesodermal derivation, capable of self-renewal and
multilineage differentiation (e.g., into osteoblasts, adipo-
cytes, and chondrocytes). MSCs are found throughout
the body and numerous extraction protocols have been
established for different tissues (e.g., umbilical cord, adi-
pose tissue, skeletal muscle, deciduous teeth, and other
tissue) [20, 21, 23, 24, 31, 32]. For more than 40 years,
bone marrow-derived stem cells have been the most
frequent sources for cell therapy. These cells can be iso-
lated from bone marrow and from bone chips (cortical
or trabecular bone). If seeded onto or cultivated on
calcium phosphate ceramic matrices in vitro, these cells
can induce bone formation in vivo [14, 33–35]. For
many years, biphasic calcium phosphate (BCP) has been
used alone or in combination with autologous bone
chips to reconstruct the floor of the maxillary sinus and
to fill extraction sockets [36, 37].
Recent preclinical studies have shown that BCP cer-
amics consisting of 20% hydroxyapatite (HA) and 80%
beta tricalcium phosphate (β-TCP) are appropriate
matrices for MSC culture in vitro and bone formation in
vivo [38, 39]. In the present clinical study, the maxillo-
facial region was selected as an appropriate site for
evaluating the safety and feasibility of using MSCs and
BCP as a new therapeutic approach to regenerate alveo-
lar bone defects. There were several reasons for this
selection. Firstly, repair of facial bone defects is a major
clinical challenge [40]. Currently, therapeutic options for
repairing large, critical-sized defects are limited to auto-
grafts, allografts, or transplanting vascularized bone and
soft tissue from autologous secondary sites [40]. Sec-
ondly, while a functional dentition is part of the normal
facial anatomy, loss of teeth initiates a process of con-
tinuous resorption of the alveolar ridge. This is acceler-
ated by denture wear and often results in pronounced
loss of bone volume and reduction in the strength of re-
sidual bone in the edentulous area. Thirdly, reconstruc-
tion of the severely atrophic mandible to restore oral
function remains a difficult surgical and prosthetic chal-
lenge because of the minimal residual bony volume and
the progressive nature of the resorption process [41–43].
Although only a small proportion of edentulous people
need bone augmentation for implant installation, for the
patients who do, the procedure is essential for restor-
ation of oral function and treatment options are limited
[10]. Finally, the implant installation procedure makes it
ethically acceptable to biopsy the implant site to inspect
the quality of newly formed bone.
The present clinical trial in humans introduced a
novel bone augmentation protocol. The primary aim
was to introduce and validate the protocol, which
uses bone marrow-derived MSCs for the clinical trial
and synthetic BCP in a standardized, minimally inva-
sive surgical procedure, and to assess the feasibility,
safety, and efficacy of this new procedure. The autolo-
gous cells were harvested and cultured for 3 weeks
before being implanted into the defect sites. The sec-
ondary outcome was to install dental implants in the
augmented alveolar bone and screw-retain a fixed
partial denture on the implants.
Methods
Ethical approval
This study conforms with the Declaration of Helsinki,
and was approved by the Norwegian ethical committee
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(2013/1284/REK Vest, University of Bergen) and by the
Norwegian Medicines Agency (13/12062-15; EudraCT
2012-003139-50). The clinical trial followed the European
guidelines for advanced therapeutic medicinal products
(ClinicalTrials.gov, NCT 02751125; https://clinicaltrials.-
gov/ct2/show/NCT02751125).
Two experienced clinicians informed the patients
about the study. After signing the consent form, the
patients underwent clinical examination, including
clinical photographs and dental impressions, and
provided a medical history. If the patient met the in-
clusion criteria, cone beam computer tomography
(CBCT) (Morita 3D Accuitomo F17, Japan) and den-
tal X-ray scans were taken.
Study design and participants
Thirteen patients were recruited for this clinical study at
the Section of Oral and Maxillofacial Surgery, Department
of Clinical Dentistry, University of Bergen, Norway. To
be eligible, the patients had to be healthy nonsmokers,
with blood tests showing no evidence of infectious dis-
eases, aged between 18 and 80 years, missing one or
more teeth in the mandibular posterior region, and
have an alveolar ridge width in the edentulous area less
than 4.5 mm. All participants provided written in-
formed consent before any study-related intervention.
The study design and time points for each intervention
are presented in Table 1.
Inclusion criteria
 Patients presenting with a subjective indication for a
fixed implant-retained prosthesis in the mandibular
posterior region (i.e., distal to the canine).
 Extensive lateral bone loss of the edentulous alveolar
ridge.
 Edentulous alveolar ridge width less than 4.5 mm.
 Edentulous for more than 6 months in the region
requiring reconstruction.
 At least one missing tooth to be replaced in the
edentulous area.
 Absence of clinical signs of infection in the region
requiring reconstruction.
 Absence of any major oral pathology.
 Age 18 years and older.
 In good health.
Exclusion criteria
 Evidence of infection with HIV, or hepatitis B or C,
or any contagious disease (specifically, serologically
negative for anti-HIV 1–2 Ab, anti-HCV Ab, HBs
Ag, anti-HBc syphilis, and negative (not detected by
PCR) in HIV NAT, HCV NAT, or HBV NAT).
 Smoker.
 Pregnant or breastfeeding.
 Untreated infections.
 History of malignancy.
Table 1 Study design and time schedule for the intervention
Intervention Day –21 (pre inclusion
visit or earlier)
Day 0 (inclusion visit) Days 12–14 Month 1 Month 6 Month 9 Month 18
Verification of the selection criteria,
information given to the patient,
patient records and informed
consent obtained
X
Panoramic X-ray scans X X X X
Loco-regional clinical examination X X X X X X X
Impression of both dental arches X X
Facial and oral cavity photographs X X
Dental radiographs X X X X
VAS score for pain X X X X X
Questionnaire on use of painkillers X X X X X
Bone marrow harvest X
Grafting procedure X
CBCT scan X X X X
Implant placement, bone biopsy X
Resonance frequency Analysis (ISQ RFA) X X X
Implant loading (prosthesis) X
Adverse events, clinical examination X X X X X X
VAS visual analog scale, CBCT cone beam computer tomography, ISQ implant stability quotient, RFA resonance frequency analysis
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 History of or scheduled cervico-facial radiation therapy.
 Chronic treatment with steroids,
immunomodulatory drugs, or bisphosphonates.
Cell production
In 13 participants, bone marrow aspirates were harvested
from the posterior iliac crest under local anesthesia at The
Adult Clinical Trial Unit at Haukeland University Hos-
pital, Bergen, Norway using a trocar to make two or three
cutaneous punctures. Each bone marrow sample was har-
vested in fractions of 2–4 ml in 20-ml syringes prefilled
with 1000 IU of heparin (Leo Pharma A/S, Denmark) and
sealed with a Luer lock stopper (Omnifix 20 ml Luer Lock
Solo; B. Braun Melsungen AG, Melsungen, Germany). A
total of 15–20 ml of bone marrow aspirate from each
patient was transported at 21 ± 3 °C with temperature
recording and monitoring to provide traceability, and dis-
patched by a special courier service to the cell manufac-
turing center at the Institute for Clinical Transfusion
Medicine and Immunogenetics (IKT), Ulm, Germany.
This center has a production license for MSCs from BM as-
pirates (production license DE_BW_01_MIA_2013_0040/
DE_BW_01_IKT Ulm), using Good Manufacturing Prac-
tices (GMP), according to defined standard operating proce-
dures and in compliance with the established quality
management system. The advanced therapy medicinal prod-
uct MSCs were manufactured at IKT Ulm as previously
described by Fekete et al. [44].
On arrival in Ulm, BM aspirates from the syringes were
pooled and a cell count of the bone marrow was performed
using an automated hematology analyzer (Sysmex
KX-21 N; Sysmex Deutschland GmbH, Norderstedt,
Germany) before any manipulation. Viability was evaluated
by flow cytometry following 7-amino-actinomycin D stain-
ing (FC500 flow cytometer; Beckman Coulter, USA). If the
total white blood cell (WBC) count was less than 127.2 ×
106 cells, the sample was considered inadequate for pro-
cessing. Viability of MSCs (passage 0 and passage 1) was
evaluated by Trypan blue staining (Sigma, Taufkirchen,
Germany). All manipulations were conducted under lam-
inar hood flow in grade A clean room conditions. The
expansion was carried out as previously described [44]. In
brief, the cell expansion started with 15–20 ml of bone
marrow aspirate; the cells were seeded on one to eight
2-chamber CellSTACKs (Corning/Fisher Scientific,
Schwerte, Germany) at a density of 50,000 WBCs/cm2
in Minimal Essential Medium alpha modification
(αMEM) (Lonza, Basel, Switzerland), supplemented
with 5% human platelet lysate (PL; IKT Ulm) and
1 IU/ml heparin (Ratiopharm, Ulm, Germany) for
14 days. The cells were then detached using trypsin
(TrypZEAN; Lonza). The harvested passage 0 cells
(MSC-P0) were counted and reseeded on one to seven
2-chamber CellSTACKs at a density of 4000 MSC-P0/cm2
in αMEM supplemented with 8% human platelet lysate
and 1 IU/ml heparin (Ratiopharm) for 7 days. The cells
were detached and passage 1 MSCs were washed with
phosphate buffered saline without Ca2+/Mg2+ (Lonza),
resuspended in a concentration of 20 × 106 MSCs/ml in
clinical-grade physiological saline (Kochsalz 0.9%
INJ.-FL.(injection fluid), 50 ml; B. Braun Melsungen AG)
supplemented with 4–5% human serum albumin (CSL
Behring, Munich, Germany). Doses of 5 ml were drawn
into one or two sterile syringes sealed with a Luer lock
stopper. Transport was undertaken by a certified shipping
company (World Courier, Stuttgart, Germany) as an ac-
companied transport to the clinical unit at the Depart-
ment of Oral and Maxillofacial Surgery, Institute of
Clinical Dentistry, University of Bergen, within 24 h of
production. Appropriate quality controls of the cell ther-
apy product were conducted after each step of the culture
procedure. Viability and the number of cells were con-
ducted using a Trypan blue viability test and a Countess
Automated Cell Counter (Countess™; Invitrogen, Life
Technologies, USA) respectively. Details on manufactur-
ing the MSCs including quality controls are presented in a
separate manuscript (Rojewski et al., submitted).
Clinical procedures
All procedures were carried out under local anesthesia
by an experienced surgeon (CG). CBCT scans were
taken for each patient using a CBCT scanner (Morita 3D
Accuitomo F17, Japan) to evaluate the bone volume
before (T0) and 4–6 months after grafting (T1). One
hour preoperatively, the patients received 1 g amoxicillin
orally (or 300 mg clindamycin if allergic to penicillin).
The site was surgically prepared under local anesthesia
(Xylocain/adrenalin 2%; Astra Zenical AS, Sweden). A
flap was raised and the cortical bone was then perforated
with a small round burr, to enhance blood flow and facili-
tate vascular ingrowth into the biomaterials (Fig. 2A).
Titanium-reinforced, nonresorbable polytetrafluoroethyl-
ene (PTFE) (Cytoplast; Osteogenics Biomedical, Lub-
bock, TX, USA) membranes were then fixed to the
underlying bone by micro-screws and mini-screws (Biomet,
Jacksonville, FL, USA) to provide a “tenting” effect [45–47].
For each patient, 5 cm3 of BCP (MBCP+™; Bioma-
tlante, France), comprising 20% HA and 80% β-TCP in
the form of granules 0.5–1 mm in size and packed in
two syringes, were used and mixed with 100 million
MSCs at the time of surgery. During this step, MSCs
attached to the BCP granules in the syringes within a
contact time of 60 min. The final number of cells mixed
with BCP was in a dose of 20 × 106 cells/1 cm3 [39]. When
the graft was ready to be inserted, the BCP granules loaded
with MSCs were withdrawn from the syringe and immedi-
ately inserted into the implant site (Fig.2B). Part of the mix-
ture was preserved for additional analyses, particularly
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bacteriological tests and cell attachment on BCP. For cell
attachment, the fluorescent dye DAPI (Sigma-Aldrich),
which binds selectively to DNA and forms strongly
fluorescent DNA–DAPI complexes, was used. The
cell-seeded material was introduced into the pocket
formed by the bony ridge and the regenerative mem-
brane and then covered by the membrane and
muco-periosteal flaps (Fig. 2C). Finally, the flaps were
sutured to the vestibular mucosa using nonabsorbable
sutures (4/0 Supramide; B. Braun Surgical SA, Spain).
The patients were instructed to eat only soft food for
the next 10–14 days, and to rinse daily with chlorhexi-
dine. The antibiotics were continued for 7 days. If neces-
sary, pain was managed by oral administration of
paracetamol (1 g tablets) or codeine phosphate sesquihy-
drate (30 mg) four times per day.
The operation site was examined clinically and the su-
tures were removed 12 days after surgery. CBCT scans
were taken of the augmented area (T1). The patients
were recalled for clinical examination after 1, 2, and 4
months (Fig. 2D). CBCT scans were taken 4–6 months
postoperatively to determine whether the sites were
ready for implant installation.
At the time of implant installation the augmented area
was reentered if the width was 7 mm or more (Fig. 2E). Prior
to implant installation, bone biopsies were taken under local
anesthesia: new bone formation was assessed by histology
and micro-computed tomography (μ-CT) (Skyscan 1172;
Bruker) at 40 kV and 2.4-μm voxel size. Dental implants
(Bone Level, Roxolid®, SLActive®; Institut Straumann AG, Ba-
sel, Switzerland) with a diameter of 4.1 mm and a length of
8–10 mm were then installed according to the manufac-
turer’s recommendations (Fig. 2F). Abutment surgery
was done 2 months after implant installation (Fig.
2G) and a screw-retained crown was mounted 2–
4 weeks later (Fig. 2H). The implant stability quotient
(ISQ) was measured at each of these procedures using
an Ostell® device (Ostell AB, Gothenburg, Sweden).
Bone volume measurements and CBCT analyses
CBCT scans (Morita 3D Accuitomo F17, Japan) were
taken before grafting (T0) and 6 months after grafting
(T1), at 85 kVp, 9.5 mA with a field of view (FOV) of
6 cm × 6 cm (diameter × height), scanning time of
17.5 s, and a voxel size of 0.125 mm.
Reconstruction of 3-dimensional models
The DICOM files of the images were then imported to
Mimics program 19.0 (Materialize NV, Leuven, Belgium).
The threshold of each case was selected manually, based
on subjective evaluation of the apparent display of the
residual jaw bone and the graft, this defined the boundary
of the region of interest (ROI) of each case. The mask of
the ROI at T0 was achieved and visualized in axial,
sagittal, and coronal views. The 2D masks were then
transformed into 3D models using the so-called “calculate
3D” function. The volume in cubic millimeters of the graft
models was acquired automatically with a display of a
color-coded 3D model.
The superimposition of the images at T0 and T1 was
applied to the Standard Tessellation Language (STL)
registration method [48]. Once the models were opti-
mally superimposed, 3D models were reconstructed
from the same region in the T0 and T1 images, specify-
ing the augmented bone volumes (ROI).
Processing bone biopsies
Micro-computed topography analyses
The bone biopsy specimens were maintained in 10%
buffered formalin. Selected bone biopsies were scanned
with the high-resolution μ-CT SkyScan1172® (SkyScan,
Kontich, Belgium) with the following technical parame-
ters: 100 mA and 100 kV power intensity, copper–alu-
mina filter and 360° rotation, and pixel size or resolution
for acquisition and image reconstruction of 2.7 μm. Im-
ages from the scanning of biopsies were reconstructed
by the software NRecon® (SkyScan) to obtain 2D and 3D
images. CTvox (version 3.2; SkyScan) was employed to
create 3D images for the biopsies. The analyzed histo-
morphometric parameters have been described previously
[49]: bone volume (BV); tissue volume (TV); bone volu-
metric fraction (BV/TV); trabecular thickness (Tb.Th), the
mean thickness of the trabeculae in the volume of interest
(VOI); trabecular separation (Tb.Sp), the mean separation
of the trabeculae in the VOI; structural model index
(SMI), which gives information about the preponderance
of trabecular morphology; degree of anisotropy (DA),
which is the presence or absence of aligned trabeculae in a
particular direction (1 is considered isotropic, > 1 is
considered anisotropic); and fractal dimension (FD), which
indicates the complexity of the specimen surface.
Histological analyses
Fixed samples were decalcified in a pH 7.4 solution con-
taining 4.13% EDTA/0.2% PFA in PBS for 96 h at 50 °C,
using an automated microwave decalcifying apparatus
(KOS Histostation; Milestone Med. Corp., USA). Sam-
ples were dehydrated in an ascending series of ethanol
followed by butanol in an automated dehydration station
(MicromMicrotech, Lyon, France). The samples were
embedded in paraffin (Histowax; Histolab, Gothenburg,
Sweden). Thin histological sections (3 μm thick) were
made using a standard microtome (Leica RM2255;
Leica Biosystems, Nanterre, France). The sections were
stained by the Masson trichrome technique, which
colors cell nuclei blue/black with hematoxylin, colors
cytoplasm, muscle, and erythrocytes red using fuchsine,
and colors collagen green using light green solution.
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Slides were scanned (NanoZoomer; Hamamatsu, Photonics,
Hamamatsu City, Shizuoka, Japan) and observed virtually
(NDP view; Hamamatsu). Histomorphometry of images was
performed using ImageJ and the percentages of bone and
bone marrow were calculated per area of explants. Four
sections through each biopsy were analyzed and quantified.
Statistical analysis
Bone width and volume are presented as means and
confidence intervals. Confidence intervals were based on
formulas assuming normal distributed data. The p value
was calculated from a one-sample t test, with 0 as the
hypothesized difference. p < 0.05 was considered statisti-
cally significant.
Outcomes
The primary outcomes of the trial were safety and feasi-
bility of the procedure, assessed 12 months after recon-
struction. In order to evaluate safety, a system was
established for reporting adverse events. With guidance
from the European Medicines Agency, these events were
further classified into serious adverse events or serious
adverse reactions. Adverse events, local (e.g., infection or
hematomas) or systemic (e.g., fever or allergic reaction),
were to be managed according to the Guidelines for
Good Clinical Practice from the International Confer-
ence on Harmonization and the German Verordnung
über klinische Versuche mit Heilmitteln. The feasibility
of the procedure was evaluated on the basis of two
factors: surgical manipulation of the graft and the ability
to install the implants as planned.
Secondary outcomes were osseointegration of the den-
tal implant and function of the prosthetic restoration.
Results
The final cell product consisted of fresh autologous cells
(MSCs) expanded in vitro expressing the markers CD90,
CD73, and CD105 and negative for CD14 and CD45,
with a 90% viability rate. The product also showed
strong expression of markers CD49d, CD73, CD90, and
CD105; moderate expression of CD14 and CD106; and
low expression of CD19, CD34, and CD45.
The viability of the cells on arrival in the operating
theater was 87–90% as demonstrated using Trypan blue
assay and cell counting. The mixing was undertaken in
theater by the surgeon, under aseptic surgical condi-
tions (Fig. 1A, B). Cells were mixed and attached well to
the BCP granules within 60 min (Fig. 1C, D).
Between June 2014 and December 2015, 13 patients
aged 52–75 years (mean 65 years) were enrolled. For 11
of the 13 patients the expansions fulfilled the release
criteria and cells could be delivered to the Department
of Oral and Maxillofacial Surgery in Bergen. Two expan-
sions were stopped at passage 0 because there were
insufficient bone marrow cells in the starting material
for expansion (Patients 5 and 10, Table 2).
All 11 patients had uneventful healing of the augmented
area, without any local infection.
No adverse events occurred during the trial period.
Moreover, the soft tissues covering the augmented bone
showed an increased area of keratinized gingiva, provid-
ing a healthy soft tissue profile (Fig. 2d). Finally, the
amount of new bone was strongly influenced by the pos-
ition of the membrane.
All 11 patients had successful ridge augmentation and
an adequate amount of bone for dental implant installa-
tion (Table 3). In five patients the PTFE membrane
Fig. 1 Cell attachment assay. A Syringes containing BCP granules (a) and MSCs (b). B Mixture of BCP and MSCs. C, D Cell attachment to
biomaterial determined using DAPI staining after arrival at operating theater
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became exposed and was removed uneventfully 7–8 weeks
post augmentation.
Casts of the alveolar ridge in each patient, X-ray scans,
and clinical examinations demonstrated a significant in-
crease of the total bone volume in all 11 patients after
treatment (Fig. 3a, b).
Linear measurements of the width and height were per-
formed from all CBCT scans in iView software (version
2.2.0.3. J; Morita MFG Corporation). Grafted bone could
easily be distinguished from residual bone by density and
structure on the scans taken immediately after the grafting
procedure. As these measurements are known to be oper-
ator dependent, the measurements were all done by one
specialist in oral radiology (SS) [50, 51]. All patients had
sufficient increase in alveolar width to have dental im-
plants installed (Fig. 4 and Table 3). The average volume
of bone increased by 887.23 ± 365.01 mm3 (Table 3). Both
the increase in width of the alveolar ridge and the increase
in volume of the alveolar ridge were statistically signifi-
cant. The mean increase in bone width (n = 14) was
4.05 mm (95% CI 2.74, 5.36; p < 0.001) and the mean in-
crease in volume (n = 14) was 887.23 mm3 (95% CI 676,
1097.98; p < 0.001).
Formation of mineralized tissues was evaluated by μ-CT
and histology from the biopsies taken during implant instal-
lation. From the μ-CT scan datasets, 3D models were built
for visualization (Fig. 5A). It was possible to identify







aspirate in passage 1
Overall harvest after
culture passage 1
1 3.46E + 03 2.98E + 04 3.06E + 08
2 1.13E + 04 1.52E + 05 4.12E + 08
3 3.59E + 03 2.89E + 04 2.46E + 08
4 1.83E + 04 2.44E + 05 4.05E + 08
5 5.74E + 01 -a -a
6 4.77E + 03 6.27E + 04 4.02E + 08
7 5.03E + 02 5.27E + 03 5.33E + 07
8 1.61E + 03 2.26E + 04 2.86E + 08
9 1,64E + 03 1.67E + 04 1.55E + 08
10 -b -a -a
11 6.54E + 03 7.67E + 04 2.42E + 08
12 2.70E + 03 2.85E + 04 2.69E + 08
13 3.63E + 03 2.79E + 04 2.34E + 08
Mean 4.84E + 03 6.32E + 04 2.74E + 08
SD 4.98E + 03 6.91E + 04 1.04E + 08
BMSC bone marrow-derived mesenchymal stromal cell, BM bone marrow, MNC
mononuclear cell, SD standard deviation
aNo colony-forming unit fibroblast CFU-F growth
bInsufficient cell count
Fig. 2 Clinical procedure. a Narrow alveolar ridge before augmentation (arrow). b Mixture of BCP and MSCs placed on alveolar ridge. c
Membrane placed over transplanted graft. d Soft tissue healing after 5 months. e New alveolar ridge after 5 months of healing. f Core biopsy
taken and dental implant installed on newly formed bone. g Eight months post augmentation and 2 months after implant installation. h Implant-
supported crown in occlusion
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accurately the newly formed bone from the BCP granules
(based on histogram calculations) when the raw data-re-
constructed cross-sections were turned into images.
Histological analysis revealed that BCP granules were
well integrated with deposition of newly formed bone tis-
sue on the surface of the particles with osteoblast lining
cells and subsequent deposition of lamellar bone tissue
(Fig. 5B). The BCP granules demonstrated continuous
degradation and dissolution, with the presence of multinu-
cleated cells, probably osteoclasts, as well as macrophage
CD68+ cells on the surface of the particles.
Table 4 presents the mean values for each analyzed
variable obtained by μ-CT analyses in relation to the
microstructural properties of the biopsies.
All patients were satisfied with the esthetic and
functional outcomes and no adverse events were re-
ported or observed. There were no postoperative in-
fections in any of the transplants or at the donor site.
One patient reported moderate levels of pain after
augmentation and after the exposed membrane had to
be removed. The other patients reported only minor
pain postoperatively. All patients were satisfied with
the clinical outcome of the augmentation procedure
and with their new teeth. All patients said they would
recommend this procedure to others with a similar
clinical condition. Ostell values increased for all pa-
tients during the first 12 months after installation of
the dental implants (Fig. 6).
Table 3 Clinical outcomes: demonstrates bone healing, increased bone width and volume












1 75 F 27 4.5 902.92 Yes Yes Yes
2 67 M 25 3.7 1047.15 Yes Yes Yes
3 55 F 26 3.9 1382.54 Yes Yes Yes
4 62 F 18 1.1 440.93 Yes Yes Yes
6 52 M 21 4.9 1469.53 Yes Yes Yes
7 left 69 M 31 4.6 432.7 Yes Yes Yes
7 right 69 M 31 4.9 1187.21 Yes Yes Yes
8 69 M 22 1.4 753.52 Yes Yes Yes
9 61 F 22 1.4 546.33 Yes Yes Yes
11 62 F 21 9.7 1188.47 Yes Yes Yes
12 left 65 F 20 2.7 954.98 Yes Yes Yes
12 right 65 F 20 3.4 418.36 Yes Yes Yes
13 left 69 F 22 3.7 553.56 Yes Yes Yes
13 right 69 F 22 6.8 1142.96 Yes Yes Yes
All patients received implants and prostheses
F female, M male
Fig. 3 Cast of alveolar ridge. Before (a) and after (b) augmentation illustrating amount of bone reconstructed. Arrows indicate the width of the alveolar ridge
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Discussion
Successful augmentation of alveolar bone was observed
in all study participants in this clinical trial of a novel
protocol using bone marrow-derived MSCs. The site se-
lected for bone augmentation was the posterior man-
dibular ridge. This is one of the most challenging sites
for reconstruction, because of the relatively limited
blood supply [52, 53], nonsterile environment [54], and
oral functions such as chewing, speaking, and swallow-
ing, which interfere with the stability of the graft.
Despite these obstacles and the use of granules as scaf-
folding, we succeeded in inducing the formation of
significant new bone and increasing the volume of the
alveolar ridge.
Horizontal bone augmentation of the alveolar ridge is
considered to be predictable, whereas vertical augmenta-
tion is not [55, 56]. Major drawbacks in relation to the
bone graft treatment are donor side morbidity, limited
amount of bone to be harvested, and unpredictable re-
sorption of the graft [7, 57–62]. Using the stem cell/bio-
material approach in the present trial promoted both
horizontal and vertical augmentation [56]. The donor site
morbidity reported by the patients was minimal. The nov-
elty of this approach was related to the development of an
appropriate protocol to produce clinical-grade cells that
could be used successfully for bone regeneration. The
MSCs were expanded using no osteogenic factors,
and no osteogenic factors were used in the clinical
procedure [63–65], as growth factors may have differ-
ent effects on different tissue [66] and also increase
the cost of producing the cells.
In preclinical studies, MSCs were expanded and pro-
duced by the manufacturing center according to the
protocol used in this clinical trial. Cells were shipped
within 24 h and applied fresh in different animal models
to demonstrate the formation of new bone in combin-
ation with the BCP biomaterial [39, 67]: the biomaterial
alone fails to bridge bone defects in critical size calvarial
defects in nude mice while full bridging was achieved
with MSC/BCP combinations [39]. However, formation
of bone seems to be dependent on a critical number of
cells or a critical cell-to-biomaterial ratio. The number
of cells and the cell-to-biomaterial BCP ratio used in this
clinical study were adapted from the preclinical findings,
where 20 × 106 MSCs were mixed with 1 cm3 BCP [39].
We believe that the intrinsic capacity of MSCs to form
bone makes the trial reproducible and safer, because the
cells were not manipulated. However, a positive effect on
osteogenic “predifferentiation” of MSCs using PL as a
supplement during the isolation and expansion phases
Fig. 4 CBCT measurements. Overlapping of bone outline contours of superimposed models at T0 (before grafting, green) (a) and T1 (6 months
after grafting, red) (b), achieved and viewed in axial (c), sagittal (d), and coronal (e) images of ridge before and after reconstruction
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cannot be excluded, although this has been a some-
what controversial topic [68, 69]. In this clinical
trial, PL was produced from up to 80 individual do-
nors: as shown in a recent study, this minimizes var-
iations in the content of growth factors, chemokines,
and cytokines [44] and ensures stable conditions for
the ex-vivo expansion of MSCs.
Two of the patients had insufficient cell expansion in
vitro, perhaps due to the variable content of MSCs
(CFU-F) in bone marrow aspirates from different
Table 4 Mean values for each analyzed variable in relation to microstructural properties of the biopsies
Patient TV (mm3) BV (mm3) BV/TV (%) Th.Tb (mm) Tb.Sp (mm) SMI DA FD
1 5.187 1.2 23.131 0.023 0.131 0.542 1.153 2.63
2 5.436 0.961 17.677 0.046 0.251 0.277 1.29 2.485
3 4.717 0.495 10.501 0.004 0.359 0.742 1.367 2.256
4 5.333 0.963 18.055 0.039 0.288 0.354 1.256 2.467
5 5.358 0.791 14.762 0.033 0.279 0.529 1.107 2.422
7 4.933 0.741 15.022 0.031 0.239 0.215 1.410 2.46
8 5.546 0.881 15.891 0.045 0.255 0.812 1.549 2.46
9 4.413 0.568 12.867 0.032 0.25 0.437 1.333 2.390
11 5.064 1.106 21.844 0.051 0.180 0.740 1.144 2.542
12 5.488 0.567 10.317 0.037 0.246 0.609 1.333 2.433
In Patient 13, the biopsy disintegrated during transport and could not be measured. However, all dental implants have osseointegrated and are still in successful
clinical function
TV tissue volume, BV bone volume, BV/TV bone volumetric fraction, Tb.Sp trabecular separation, Th.Tb Trabercular thickness, SMI structural model index, DA degree
of anisotropy, FD fractal dimension
Fig. 5 μ-CT and histological analyses. A μ-CT images of biopsies from Patients 1–10. B Histology of core biopsies from patients. Note abundant
lamellar bone with entrapped osteocytes in extracellular matrix at high magnification around remaining BCP particles (*). a, c Hematoxylin and
eosin staining, b, d Masson trichrome staining. Magnification ×1.25 and ×10
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individuals [65]. This variability may be a limiting step in
the procedure, but may be overcome by increasing the
number of cells harvested or by developing methods for
identifying the relevant cells prior to initiating culture.
There are few published papers on mandibular and
maxillary defect reconstruction using bone marrow or
adipose-derived stem cells [33, 70–77], many of which
are case reports [70, 74, 75, 77]. The published studies
vary in cell source, defect site, scaffold material, cell
number, use of growth factors, and membrane or hard-
ware [33, 70, 74–79]. However, the present data gener-
ated by treating 11 cases differ from these earlier reports
as no growth factor or stimulants were used on the cells
prior to implantation. Furthermore, the posterior man-
dibular region (i.e., distal to the canine) in all patients
was selected as an inclusion criterion, as the bone heal-
ing is dependent on the location of the defected bone.
Although the membrane was the determinant of aug-
mentation volume, it complicated the surgical procedure
and postoperative healing procedure. The high-density
membrane is microporous, impervious to bacteria while
still allowing diffusion of gases and small molecules, but
probably inhibits vascularization from the periosteum,
limiting the blood supply to the graft. The granules that
remained outside the compartment made by the mem-
brane did not induce bone formation, indicating the im-
portance of using an appropriate membrane. Further
supporting the importance of the membrane in bone
formation, a study by Meijer et al. [76] using no mem-
brane and grafts of bone marrow MSCs grown for 7 days
in osteogenic medium and loaded with ceramic bone
substitutes did not succeed in inducing bone formation.
In a randomized, controlled trial reported recently,
osseous defects generated after tooth extraction were
treated successfully with bone marrow-derived cells
loaded on gelatin sponge. They showed accelerated heal-
ing after 6 weeks, but no significant difference after
12 weeks compared to no cells applied to the defect
[33]. However, it is well known that extraction sockets
heal without intervention [58, 80].
In the present study, the volumetric measurement on
CBCT images was a visual protocol for assessing the
outcome of grafting. The volumetric changes to the bone
were achieved at T0 and T1. The objective measurement
on CBCT images was performed to confirm the clinic-
ally observed volumetric changes in the graft [81–83].
This methodology has also been used in follow-up after
grafting procedures in alveolar cleft patients [84–86].
Further, the biopsy specimens taken 4–6 months after
augmentation showed significant new bone formation,
with abundant blood supply and without inflammatory
cells. The BCP scaffold was still visible in the histological
samples as the reported resorption time is up to 2 years
[38]. The scaffold material provides the extracellular
microenvironment for support and stimulation of the
cells, and also acts as the delivery system for the cells
[18]. Although no direct evidence is provided relative to
the source of the cells that produced the regenerated tis-
sue (i.e., labeling of the cells), the assumption can be
made that the transplanted cells at least partly contrib-
uted to bone regeneration, because the bone core speci-
men was taken from the central region of the defect and
graft site.
Normally, there is a gradual resorption of keratinized
mucosa simultaneously with bone resorption and this re-
sorbed keratinized mucosa is known to not regenerate
[87, 88]. The presence of keratinized mucosa of at least
1–2 mm around an implant is beneficial in decreasing
Fig. 6 Ostell measurements. Implant installation (T0), at loading (T1), and at 18 months follow-up (T2). Data presented as mean ± SD showing
increased implant stability after loading
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plaque accumulation, tissue inflammation, and attach-
ment loss [87, 89]. In our patients, an unexpected bene-
fit of the augmentation procedure was an increase in the
width of keratinized mucosa (Fig. 2d, g). It therefore ap-
pears that the cells used to regenerate bone also have a
positive effect on neighboring soft tissues and contribute
to wound healing, even when covered by a membrane.
MSCs have demonstrated a beneficial effect on wound
healing [90, 91]. This observation warrants further inves-
tigation. However, MSCs have demonstrated a beneficial
effect on wound healing, which appears to be mediated
by paracrine signaling [91]. The role of paracrine factors
produced by stem cells in tissue regeneration and heal-
ing has been investigated and reports showed that angio-
genesis and osteogenesis were promoted in response to
the paracrine effect of stem cells [65, 90]. This paracrine
effect is exerted through cytokines and chemokines such
as insulin-like growth factor (IGF)-1, vascular endothe-
lial growth factor (VEGF), and transforming growth
factor (TGF)-β1. These growth factors were found to en-
hance cell proliferation, mobilization, angiogenesis, and
expression of osteogenic markers such as alkaline phos-
phatase, collagen type I, and Runx2 genes [92]. Further-
more, these factors recruit endogenous stem cells to the
grafted site [90, 92].
Because of the small cohort and follow-up time (now
up to 3 years), the promising results of this study should
be interpreted with caution. In order to validate this
treatment protocol for application in a standard clinical
setting, further study is warranted, with a larger study
cohort and a longer follow-up period. Nevertheless, the
results of this study are promising and could lead to the
development of new strategies for regenerative medicine
and therapeutic interventions, and thus have a direct
and positive impact on large groups of patients.
Conclusions
The results of this novel clinical study in human subjects
show that clinical reconstruction of the alveolar ridge
using autologous MSCs and BCP is feasible, safe, and
predictable. All sites were successfully augmented; all
dental implants osseointegrated and were restored with
screw-retained dental crowns as planned. Hence, this
novel augmentation procedure warrants further investi-
gation and may form the basis of a valid treatment
protocol, challenging the current gold standard.
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